Comparing GLIADEL and Stereotactic Radiosurgery for Metastatic Brain Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of GLIADEL, a local chemotherapy treatment, in preventing the recurrence of metastatic brain tumors after surgical resection, compared to stereotactic radiosurgery (SRS). A total of 100 adult participants with one to four metastatic brain tumors will be enrolled, with randomization occurring at the time of surgery to either receive GLIADEL or SRS. Participants will undergo pre-operative evaluations, including MRI and neuropsychological testing, and will be monitored for local recurrence and cognitive changes post-treatment. The study aims to compare the genomic characteristics of the metastatic tumors to their primary tumors.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Age 18 years or older (in states with 18 as age of majority); Age 19 years or older in Nebraska (age of majority)
* Recursive partitioning analysis (RPA) class I, II or III with a Karnofsky Performance Status (KPS) of \>/ 60
* Known or suspected primary solid cancer with metastatic brain tumor(s) - up to four in number and up to 4 cm in size with surgical resection planned for at least one site with Gliadel placement planned for only one site
* Laboratory values adequate for patient to undergo surgery safely as determined by the attending neurosurgeon (transfusion permitted to reach goals)
* Women of childbearing potential must have a negative pregnancy test within 7 days of initiating study. (No childbearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and/or both ovaries)
* Normal coagulation studies (international normalized ratio, INR, ≤ 1.3)
* Estimated survival time of ≥ 3 months (determined by the participant's primary oncologist)
* Participant is willing and able to consent and abide by the protocol

Exclusion criteria:

* Prior treatment to the area of planned resection (surgery, radiation)
* Prior whole brain radiation therapy
* Diagnosis of lymphoma, germ cell cancer, small cell lung cancer, anaplastic thyroid cancer
* Leptomeningeal disease
* Neurodegenerative disorder (e.g. dementia)
* Tumor size \> 4 cm
* Karnofsky Performance Status (KPS) \< 60
* Inability or unwillingness to co-operate with the requirements of the protocol
* Any other clinically significant medical disease or condition, laboratory abnormality or psychiatric illness that, in the Investigator's opinion, may interfere with protocol adherence or confound efficacy or safety assessment or a subject's ability to give informed consent
* Simultaneous participation in other therapeutic clinical trials
* Severe pulmonary, cardiac or other systemic disease, specifically:

  * New York Heart Association \> Grade 2 congestive heart failure within 6 months prior to study entry, unless asymptomatic and well controlled with medication
  * Uncontrolled or significant cardiovascular disease, clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or Torsades des pointes), clinically significant pulmonary disease (such as ≥ Grade 2 dyspnea, according to Common Terminology Criteria for Adverse Events 5.0)
* Participants having any other disease, either metabolic or psychological, which as per Investigator assessment may affect the participant's compliance or place the participant at higher risk of potential treatment complications
* Participant has a bleeding diathesis, or must take anticoagulants, or antiplatelet agents including non-steroidal anti-inflammatory drugs (NSAIDs) at the time of scheduled resection that cannot be stopped for surgery
* Inability to obtain MRI studies

Where it's running

• University of Nebraska Medical Center
  Omaha, Nebraska, United States Recruiting
• Henry Ford
  Detroit, Michigan, United States Not yet recruiting

Study contacts

• Principal investigator: Michele Aizenberg, MD — University of Nebraska
• Study coordinator: Project Coordinator
• Email: IITOffice@unmc.edu
• Phone: 402-559-0963

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Same-day stereotactic radiation with reduced planning margins for growing or changing brain metastases

  This trial will try to see if doing MRI planning and stereotactic radiation on the same day, with either a 0 mm or 1 mm treatment margin, helps adults with growing or unstable brain metastases stay on target and reduce side effects.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT07132190

• Characterizing immune cells in malignant brain tumors

  This study is trying to understand how immune cells behave in people with malignant brain tumors by looking at their blood and tumor samples before and after surgery.

  Recruiting IRCCS San Raffaele · Milan, Milan · NCT05831631

• Registry of patients with brain tumors treated with GammaTiles

  This study is testing how well GammaTiles treatment works for people with brain tumors after surgery, looking at their health and quality of life over five years.

  Recruiting at 49 sites GT Medical Technologies, Inc. · Phoenix, Arizona and 53 other locations · NCT04427384

• Belvarafenib in BRAF-altered brain tumors

  This Phase 2 study tests Belvarafenib daily to see if it can help people with BRAF-altered primary or metastatic brain tumors.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07688356

• Treatment of high-grade glioma in young patients using olutasidenib and temozolomide

  This study is testing if a new combination of olutasidenib and temozolomide can help young patients with high-grade gliomas that have a specific mutation feel better after their radiotherapy.

  Recruiting at 8 sites Phase 2 Rigel Pharmaceuticals · Aurora, Colorado and 19 other locations · NCT06161974

• Combining ribociclib and everolimus for treating high-grade gliomas in young patients

  This study is testing if a combination of two drugs, ribociclib and everolimus, can help young patients with high-grade gliomas live longer and feel better after their initial treatment.

  Recruiting at 12 sites Phase 2 Nationwide Children's Hospital · Aurora, Colorado and 19 other locations · NCT05843253

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.